SCHEMBL6344155

SCHEMBL6344155

COC(CO)c1ccc(O)c(O)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.47
ACHE P22303 1/20 0.47
CYP3A4 P08684 4/20 0.46
TSHR P16473 4/20 0.46
TDP1 Q9NUW8 10/20 0.44
MAPT P10636 9/20 0.44
KDM4E B2RXH2 8/20 0.44
RECQL P46063 7/20 0.44
KMT2A Q03164 5/20 0.44
ADRB2 P07550 5/20 0.44
APEX1 P27695 4/20 0.44
MEN1 O00255 4/20 0.44
ADRB1 P08588 4/20 0.44
ADRB3 P13945 4/20 0.44
MAPK1 P28482 4/20 0.44
MTOR P42345 4/20 0.44
ADORA3 P0DMS8 3/20 0.44
DRD2 P14416 3/20 0.44
ADRA1D P25100 3/20 0.44
ADRA1A P35348 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28957735 0.85 TDP1 (0.50) BCHEACHECYP3A4TSHRTDP1
SCHEMBL9580100 0.83 TDP1 (0.56) BCHEACHECYP3A4TSHRTDP1
Hydrochloric Acid SCHEMBL30252423 0.81 KDM4E (0.55) BCHEACHECYP3A4TSHRTDP1
SCHEMBL17253835 0.81 TDP1 (0.44) CYP3A4TSHRTDP1MAPTKDM4E
SCHEMBL13715489 0.80 TDP1 (0.62) BCHEACHECYP3A4TSHRTDP1
SCHEMBL30849924 0.80 TDP1 (0.62) BCHEACHECYP3A4TSHRTDP1
SCHEMBL22971740 0.80 TDP1 (0.62) BCHEACHECYP3A4TSHRTDP1
SCHEMBL13425968 0.78 ADRB2 (0.64) BCHEACHECYP3A4TSHRTDP1
SCHEMBL13425979 0.78 ADRB2 (0.64) BCHEACHECYP3A4TSHRTDP1
SCHEMBL29999118 0.78 BCHE (0.51) BCHEACHECYP3A4TSHRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015169980-A1 BACTERIAL STRAINS AND THE USES THEREOF IN ACYLATION AND/OR DEACYLATION REACTIONS UNIVERSIDAD DE SEVILLA (ES) 2015-11-12 WO disclosed
US-6906100-B2 Compounds and compositions derived from olives and methods of the use thereof LAVIPHARM S.A. (GR) 2005-06-14 US disclosed
EP-1474130-A2 USE OF COMPOUNDS AND COMPOSITIONS DERIVED FROM OLIVES FOR PROTECTING CELLS AGAINST DNA DAMAGE LAVIPHARM S.A. (GR) 2004-11-10 EP disclosed
US-20030185921-A1 COMPOUNDS AND COMPOSITIONS DERIVED FROM OLIVES AND METHODS OF USE THEREOF THALLIUM HOLDING COMPANY, LLC 2003-10-02 US disclosed
WO-2003066034-A2 USE OF COMPOUNDS AND COMPOSITIONS DERIVED FORM OLIVES FOR PROTECTING CELLS AGAINST DNA DAMAGE LAVIPHARM S.A. (GR) 2003-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030185921-A1 COMPOUNDS AND COMPOSITIONS DERIVED FROM OLIVES AND METHODS OF USE THEREOF OGG1, SOD3, LIG3 BCHE 2500/4885ACHE 899/4885CYP3A4 4148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.